Genetic modification of T lymphocytes for adoptive immunotherapy

Molecular Therapy

Volumn 10, Issue 1, 2004, Pages 5-18

  Rossig, Claudia ^a   Brenner, Malcolm K ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CYCLIN DEPENDENT KINASE 1; DEOXYCYTIDINE; FK 506 BINDING PROTEIN; GANCICLOVIR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYGROMYCIN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; IRINOTECAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; MUTANT PROTEIN; PHOSPHOTRANSFERASE; PROTEIN ANTIBODY; REV PROTEIN ANTIBODY; RIBOZYME; RITUXIMAB; T LYMPHOCYTE RECEPTOR; THYMIDINE KINASE; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIVIRAL ACTIVITY; CANCER IMMUNOTHERAPY; CELL FUNCTION; CLINICAL TRIAL; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; GENE TRANSFER; GENE VECTOR; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC SYSTEM; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; NONHUMAN; REVIEW; SUICIDE GENE THERAPY; T LYMPHOCYTE; TUMOR CELL; TUMOR ESCAPE; VIRUS INFECTION;

GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 3042772669     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.04.014     Document Type: Review

References (149)

1. Goedegebuure P.S. et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma-a pilot study J. Clin. Oncol. 13 1995 1939-1949
2. Kolb H.J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 86 1995 2041-2050
3. Rooney C.M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation Lancet 345 1995 9-13
4. Rooney C.M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients Blood 92 1998 1549-1555
5. Rosenberg S.A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma-a preliminary report N. Engl. J. Med. 319 1988 1676-1680
6. Roskrow M.A. et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease Blood 91 1998 2925-2934
7. Bunnell B.A. Muul L.M. Donahue R.E. Blaese R.M. Morgan R.A. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes Proc. Natl. Acad. Sci. USA 92 1995 7739-7743
8. Gallardo H.F. Tan C. Ory D. Sadelain M. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes Blood 90 1997 952-957
9. Mavilio F. et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer Blood 83 1994 1988-1997
10. Riviere I. Brose K. Mulligan R.C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells Proc. Natl. Acad. Sci. USA 92 1995 6733-6737
11. Duarte R.F. et al. Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy Gene Ther. 9 2002 1359-1368
12. Tiberghien P. et al. Administration of herpes simplex thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft Blood 97 2001 63-72
13. Sauce D. et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms Blood 99 2002 1165-1173
14. Ferrand C. et al. Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire Hum. Gene Ther. 11 2000 1151-1164
15. Berger C. Blau C.A. Clackson T. Riddell S.R. Heimfeld S. CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy Blood 101 2003 476-484
16. + T cells from HIV-1-infected donors after CD3/CD28 costimulation J. Hematother. 7 1998 437-448
17. Maus M.V. et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB Nat. Biotechnol. 20 2002 143-148
18. Brentjens R.J. Gong M.C. Latouche J.B. Riviere I. Sadelain M. Long term survival of SCID-beige mice bearing Raji cell tumors after intravenous treatment with human T cells genetically modified to recognize the CD19 antigen Blood 98 2001 694A
19. Challita P.M. Kohn D.B. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo Proc. Natl. Acad. Sci. USA 91 1994 2567-2571
20. Hawley R.G. Lieu F.H.L. Fong A.Z.C. Hawley T.S. Versatile retroviral vectors for potential use in gene therapy Gene Ther. 1 1994 136-138
21. Rivella S. Callegari J.A. May C. Tan C.W. Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites J. Virol. 74 2000 4679-4687
22. Uckert W. et al. Efficient gene transfer into primary human CD8(+) T lymphocytes by MuLV-10A1 retrovirus pseudotype Hum. Gene Ther. 11 2000 1005-1014
23. Pollok K.E. et al. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments J. Virol. 72 1998 4882-4892
24. Papadopoulos E.B. et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone-marrow transplantation N. Engl. J. Med. 330 1994 1185-1191
25. Riddell S.R. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones Science 257 1992 238-241
26. Walter E.A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor N. Engl. J. Med. 333 1995 1038-1044
27. Kolb H.J. Schmid C. Barrett A.J. Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras Blood 103 2004 767-776
28. Theobald M. et al. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes J. Exp. Med. 185 1997 833-841
29. Rosenberg S.A. et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction N. Engl. J. Med. 323 1990 570-578
30. Dembic Z. et al. Transfer of specificity by murine alpha-T-cell and beta-T-cell receptor genes Nature 320 1986 232-238
31. Clay T.M. et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity J. Immunol. 163 1999 507-513
32. Cole D.J. et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the Mart-1 melanoma antigen Cancer Res. 55 1995 748-752
33. Calogero A. et al. Retargeting of a T cell line by anti Mage-3/HLA-A2 alpha beta TCR gene transfer Anticancer Res. 20 2000 1793-1799
34. Stanislawski T. et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer Nat. Immunol. 2 2001 962-970
35. Cooper L.J.N. Kalos M. Lewinsohn D.A. Riddell S.R. Greenberg P.D. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes J. Virol. 74 2000 8207-8212
36. Orentas R.J. Roskopf S.J. Nolan G.P. Nishimura M.I. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide Clin. Immunol. 98 2001 220-228
37. Kessels H.W.H.G. Wolkers M.C. van den Boom M.D. van der Valk M.A. Schumacher T.N.M. Immunotherapy through TCR gene transfer Nat. Immunol. 2 2001 957-961
38. Geiger T.L. Leitenberg D. Flavell R.A. The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes J. Immunol. 162 1999 5931-5939
39. Irving B.A. Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways Cell 64 1991 891-901
40. Letourneur F. Klausner R.D. Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon Science 255 1992 79-82
41. Romeo C. Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides Cell 64 1991 1037-1046
42. Eshhar Z. Waks T. Gross G. Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors Proc. Natl. Acad. Sci. USA 90 1993 720-724
43. Altenschmidt U. Klundt E. Groner B. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression J. Immunol. 159 1997 5509-5515
44. Hwu P. et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes Cancer Res. 55 1995 3369-3373
45. Kershaw M.H. Westwood J.A. Hwu P. Dual-specific T cells combine proliferation and antitumor activity Nat. Biotechnol. 20 2002 1221-1227
46. Muniappan A. Banapour B. Lebkowski J. Talib S. Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes Cancer Gene Ther. 7 2000 128-134
47. Niederman T.M.J. et al. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors Proc. Natl. Acad. Sci. USA 99 2002 7009-7014
48. Chung S. Strominger J.L. Regulation of T-cell antigen receptor (Tcr) alpha-chain expression by Tcr beta-chain transcripts Proc. Natl. Acad. Sci. USA 92 1995 3712-3716
49. Willemsen R.A. et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR Gene Ther. 7 2000 1369-1377
50. Jyothi M.D. Flavell R.A. Geiger T.L. Targeting autoantigen-specific T cells and suppression of autoimmune encephalomyelitis with receptor-modified T lymphocytes Nat. Biotechnol. 20 2002 1215-1220
51. Annenkov A. Chernajovsky Y. Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta Gene Ther. 7 2000 714-722
52. Annenkov A.E. Moyes S.P. Eshhar Z. Mageed R.A. Chernajovsky Y. Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit J. Immunol. 161 1998 6604-6613
53. Bitton N. Verrier F. Debre P. Gorochov G. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120 Eur. J. Immunol. 28 1998 4177-4187 [Published erratum appears in Eur. J. Immunol., 1996, 29: 725]
54. Hege K.M. Cooke K.S. Finer M.H. Zsebo K.M. Roberts M.R. Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice J. Exp. Med. 184 1996 2261-2269
55. + T lymphocytes armed with universal T-cell receptors Blood 84 1994 2878-2889
56. Roberts M.R. et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains J. Immunol. 161 1998 375-384
57. Mitsuyasu R.T. et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects Blood 96 2000 785-793
58. Beecham E.J. Ma Q.Z. Ripley R. Junghans R.P. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death J. Immunother. 23 2000 631-642
59. Hombach A. et al. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood T cells to specific lysis of carcinoembryonic antigen-positive tumor cells Int. J. Cancer 88 2000 115-120
60. Verhoeyen M. Milstein C. Winter G. Reshaping human antibodies-grafting an antilysozyme activity Science 239 1988 1534-1536
61. Cai X. Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries Proc. Natl. Acad. Sci. USA 92 1995 6537-6541
62. Kalams S.A. Walker B.D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses J. Exp. Med. 188 1998 2199-2204
63. Zajac A.J. Murali-Krishna K. Blattman J.N. Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4(+) and CD8(+) T cells Curr. Opin. Immunol. 10 1998 444-449
64. Hombach A. et al. CD4(+) T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion J. Immunol. 167 2001 1090-1096
65. Patel S.D. Ge Y. Moskalenko M. McArthur J.G. Anti-tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions J. Immunother. 23 2000 661-668
66. Deeks S.G. et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy Mol. Ther. 5 2002 788-797
67. Brocker T. Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes J. Exp. Med. 181 1995 1653-1659
68. Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells Blood 96 2000 1999-2001
69. Grakoui A. et al. The immunological synapse: a molecular machine controlling T cell activation Science 285 1999 221-227
70. Bretscher P. Cohn M. A theory of self-nonself discrimination Science 169 1970 1042-1049
71. Maric M. Zheng P. Sarma S. Guo Y. Liu Y. Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and nest antigen-presenting cells Cancer Res. 58 1998 3376-3384
72. Ochsenbein A.F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction Nature 411 2001 1058-1064
73. Lenschow D.J. Walunas T.L. Bluestone J.A. CD28/B7 system of T cell costimulation Annu. Rev. Immunol. 14 1996 233-258
74. Baskar S. Clements V.K. Glimcher L.H. Nabavi N. OstrandRosenberg S. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules J. Immunol. 156 1996 3821-3827
75. Li Y.W. Hellstrom K.E. Newby S.A. Chen L.P. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors J. Exp. Med. 183 1996 639-644
76. Alvarez-Vallina L. Hawkins R.E. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors Eur. J. Immunol. 26 1996 2304-2309
77. Krause A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes J. Exp. Med. 188 1998 619-626
78. Finney H.M. Lawson A.D. Bebbington C.R. Weir A.N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product J. Immunol. 161 1998 2791-2797
79. Geiger T.L. Nguyen P. Leitenberg D. Flavell R.A. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes Blood 98 2001 2364-2371
80. Hombach A. et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule J. Immunol. 167 2001 6123-6131
81. Maher J. Brentjens R.J. Gunset G. Riviere I. Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor Nat. Biotechnol. 20 2002 70-75
82. Haynes N.M. et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors Blood 100 2002 3155-3163
83. Finney H.M. Akbar A.N. Lawson A.D.G. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain J. Immunol. 172 2004 104-113
84. Nguyen P. Moisini I. Geiger T.L. Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function Blood 102 2003 4320-4325
85. Finke J.H. et al. Loss of T-cell receptor zeta-chain and P56(Lck) in T-cells infiltrating human renal cell carcinoma Cancer Res. 53 1993 5613-5616
86. Mizoguchi H. et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice Science 258 1992 1795-1798
87. Nakagomi H. et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma Cancer Res. 53 1993 5610-5612
88. Wang Q. et al. T-cells infiltrating non-Hodgkins B-cell lymphomas show altered tyrosine phosphorylation pattern even though T-cell receptor CD3-associated kinases are present J. Immunol. 155 1995 1382-1392
89. Fitzer-Attas C.J. Schindler D.G. Waks T. Eshhar Z. Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation J. Biol. Chem. 272 1997 8551-8557
90. Fitzer-Attas C.J. Schindler D.G. Waks T. Eshhar Z. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation J. Immunol. 160 1998 145-154
91. Khanna R. Burrows S.R. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases Annu. Rev. Microbiol. 54 2000 19-48
92. Rossig C. Bollard C.M. Nuchtern J.G. Rooney C.M. Brenner M.K. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy Blood 99 2002 2009-2016
93. Cooper L.J.N. et al. Adoptively transferred bi-specific T cells expanded in vivo by restimulation with a T cell vaccine can treat established B-lineage malignancy Blood 102 2004 621a [Abstract]
94. Walczak H. et al. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo Nat. Med. 5 1999 157-163
95. Ucur E. et al. Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells Br. J. Cancer 89 2003 2155-2162
96. Dilloo D. et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity Nat. Med. 2 1996 1090-1095
97. Yamada G. et al. Retroviral expression of the human IL-2 gene in a murine T-cell line results in cell-growth autonomy and tumorigenicity EMBO J. 6 1987 2705-2709
98. Karasuyama H. Tohyama N. Tada T. Autocrine growth and tumorigenicity of interleukin-2-dependent helper T-cells transfected with IL-2 gene J. Exp. Med. 169 1989 13-25
99. Hwu P. Rosenberg S.A. The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy Gene Ther. Neoplastic Dis. 716 1994 188-199
100. Hwu P. et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans J. Immunol. 150 1993 4104-4115
101. Wagner H.J. et al. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells Cancer Gene Ther. 11 2004 81-91
102. Nizard P. et al. Anchoring cytokines to tumor cells for the preparation of anticancer vaccines without gene transfection in mice J. Immunother. 26 2003 63-71
103. Gorelik L. Flavell R.A. Transforming growth factor-beta in T-cell biology Nat. Rev. Immunol. 2 2002 46-53
104. Gorelik L. Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells Nat. Med. 7 2001 1118-1122
105. Bollard C.M. et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity Blood 99 2002 3179-3187
106. Harrison L.C. Hafler D.A. Antigen-specific therapy for autoimmune disease Curr. Opin. Immunol. 12 2000 704-711
107. Shaw M.K. et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis J. Exp. Med. 185 1997 1711-1714
108. Costa G.L. et al. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit J. Immunol. 167 2001 2379-2387
109. Nakajima A. et al. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis J. Clin. Invest. 107 2001 1293-1301
110. Brodie S.J. et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells Nat. Med. 5 1999 34-41
111. Pule M. et al. Long-term safety and persistence data after infusion of retrovirally marked EBV-CTLs Blood 102 2004 745a [Abstract]
112. Altman J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes Science 274 1996 94-96
113. Tjuvajev J.G. et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography Cancer Res. 58 1998 4333-4341
114. Hardy J. et al. Bioluminescence imaging of lymphocyte trafficking in vivo Exp. Hematol. 29 2001 1353-1360
115. Koehne G. et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes Nat. Biotechnol. 21 2003 405-413
116. Ponomarev V. et al. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo Neoplasia 3 2001 480-488
117. Hacein-Bey-Abina S. et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency N. Engl. J. Med. 348 2003 255-256
118. Li Z.X. et al. Murine leukemia induced by retroviral gene marking Science 296 2002 497
119. Nakai H. et al. AAV serotype 2 vectors preferentially integrate into active genes in mice Nat. Genet. 34 2003 297-302
120. Bonini C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia Science 276 1997 1719-1724
121. Marktel S. et al. Emergence of additional chromosomal abnormalities following treatment with STI571 (imatinib mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase Blood 98 2001 617A
122. Verzeletti S. et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors Hum. Gene Ther. 9 1998 2243-2251
123. Chalmers D. et al. Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene Mol. Ther. 4 2001 146-148
124. Fehse B. et al. A novel 'sort-suicide' fusion gene vector for T cell manipulation Gene Ther. 9 2002 1633-1638
125. Introna M. et al. Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies Hum. Gene Ther. 11 2000 611-620
126. Riddell S.R. et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients Nat. Med. 2 1996 216-223
127. Aghi M. Kramm C.M. Breakefield X.O. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo J. Natl. Cancer Inst. 91 1999 1233-1241
128. Hapke D.M. Stegmann A.P.A. Mitchell B.S. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity Cancer Res. 56 1996 2343-2347
129. Kojima A. Hackett N.R. Ohwada A. Crystal R.G. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors J. Clin. Invest. 101 1998 1789-1796
130. Thomis D.C. et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease Blood 97 2001 1249-1257
131. Altenschmidt U. et al. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes Clin. Cancer Res. 2 1996 1001-1008
132. Stancovski I. et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors J. Immunol. 151 1993 6577-6582
133. Parker L.L. et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer Hum. Gene Ther. 11 2000 2377-2387
134. Wang G. et al. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen Nat. Med. 4 1998 168-172
135. Darcy P.K. Kershaw M.H. Trapani J.A. Smyth M.J. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma Eur. J. Immunol. 28 1998 1663-1672
136. Hombach A. et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA Gene Ther. 6 1999 300-304
137. Daly T. et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene Cancer Gene Ther. 7 2000 284-291
138. McGuinness R.P. et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor Hum. Gene Ther. 10 1999 165-173
139. Weijtens M.E. Willemsen R.A. Valerio D. Stam K. Bolhuis R.L. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity J. Immunol. 157 1996 836-843
140. Weijtens M.E. Willemsen R.A. van Krimpen B.A. Bolhuis R.L. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules Int. J. Cancer 77 1998 181-187
141. Weijtens M.E.M. Hart E.H. Bolhuis R.L.H. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production Gene Ther. 7 2000 35-42
142. Yun C.O. Nolan K.F. Beecham E.J. Reisfeld R.A. Junghans R.P. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors Neoplasia 2 2000 449-459
143. Rossig C. Bollard C.M. Nuchtern J.G. Merchant D.A. Brenner M.K. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes Int. J. Cancer 94 2001 228-236
144. Kershaw M.H. et al. Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature Hum. Gene Ther. 11 2000 2445-2452
145. + tumor cells by primary lymphocytes modified with chimeric T cell receptors Hum Gene Ther. 11 2000 9-19
146. Ren-Heidenreich L. Mordini R. Hayman G.T. Siebenlist R. LeFever A. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis Cancer Immunol. Immunother. 51 2002 417-423
147. Hombach A. et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T- cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30 Cancer Res. 58 1998 1116-1119
148. Hombach A. et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen J. Immunother. 22 1999 473-480
149. Cooper L.J.N. et al. T cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect Blood 101 2003 1637-1644